Skip to main content

Table 2 Details of the 6 Patients with HBV reactivation

From: Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Patients CharacteristicsBaselineAt reactivation  
PatientAge (years)GenderCancer typeAnti-tumor therapyHBV DNA (IU/mL)Antiviral prophylaxisWeeks from start of immunotherapyHBV DNA (IU/mL)Peak ALT (U/L)Anti-PD-1/PD-L1 therapy disruptionAntiviral treatmentTime for achieving HBV-DNA undetectable (weeks)Time for ALT recovery (weeks)
148MNPCCamrelizumabUndetectableNil37.81 × 103191.4DelayedEntecavir12
247MNPCCamrelizumabUndetectableNil166.98 × 104203.0DelayedEntecavir44
339MMelanomaPembrolizumabUndetectableNil282.10 × 10327.6NoNil5NA
436MHCCNivolumabUndetectableEntecavir121.80 × 103298DiscontinuedEntecavir plus tenofovir13
545MHNSCCToripalimabUndetectableNil354.04 × 106281.2DelayEntecavir36
6a41FSoft Tissue SarcomaNivolumabUndetectableNil206.00 × 107465.1NAEntecavir84
  1. aHBV reactivation in this patient occurred 6 weeks after immunotherapy was discontinued; other HBV reactivation occurred during anti-PD-1/PD-L1 thearpy
  2. Abbreviations: M male, F female, HBV hepatitis B virus, NPC nasopharyngeal carcinoma, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell cancer, ALT alanine aminotransferase, NA not applicable